← Back to Search

Behavioral Intervention

All subjects for Pulmonary Arterial Hypertension (RESIST-PH Trial)

N/A
Waitlist Available
Led By Nadine Al-Naamani, MD, MS
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Diagnosis of PAH: idiopathic, heritable, associated with connective tissue disease, congenital heart disease, human immunodeficiency virus, drug- or toxin, or portopulmonary hypertension
* On stable PAH therapy for 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of twice per year
Awards & highlights

Summary

The purpose of the study is to learn more about how low-resistance training impacts frailty and the quality of life of people with pulmonary arterial hypertension (PAH). Low-resistance training is an evidence-based approach that may help patients improve their functional ability.

Who is the study for?
This trial is for individuals with pulmonary arterial hypertension (PAH) who are experiencing frailty. The study aims to include those who can safely perform low-resistance exercises and are looking to improve their quality of life.
What is being tested?
The focus of the trial is on the effects of low-resistance training on patients with PAH. It seeks to determine if this type of exercise can reduce frailty and enhance overall well-being.
What are the potential side effects?
Low-resistance training is generally safe, but may cause muscle soreness or fatigue. People with PAH should monitor for any unusual symptoms like worsening breathlessness during the program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of twice per year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of twice per year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events
Feasibility of Recruitment
Feasibility of Study
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: All subjectsExperimental Treatment1 Intervention
All subjects will participate in the low-resistance training

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,043 Previous Clinical Trials
42,889,607 Total Patients Enrolled
7 Trials studying Pulmonary Arterial Hypertension
256 Patients Enrolled for Pulmonary Arterial Hypertension
Nadine Al-Naamani, MD, MSPrincipal InvestigatorUniversity of Pennsylvania
~13 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top